Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
RCEL 
Avita Medical Ltd (RCEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/20/2026: RCEL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.45
1 Year Target Price $8.45
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 146.73M USD | Price to earnings Ratio - | 1Y Target Price 8.45 |
Price to earnings Ratio - | 1Y Target Price 8.45 | ||
Volume (30-day avg) 4 | Beta 1.8 | 52 Weeks Range 3.22 - 10.29 | Updated Date 02/21/2026 |
52 Weeks Range 3.22 - 10.29 | Updated Date 02/21/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.74 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-02-19 | When - | Estimate -0.2617 | Actual -0.5357 |
Profitability
Profit Margin -67.85% | Operating Margin (TTM) -59.09% |
Management Effectiveness
Return on Assets (TTM) -39.06% | Return on Equity (TTM) -1746.27% |
Valuation
Trailing PE - | Forward PE 4.82 | Enterprise Value 174589293 | Price to Sales(TTM) 2.05 |
Enterprise Value 174589293 | Price to Sales(TTM) 2.05 | ||
Enterprise Value to Revenue 2.44 | Enterprise Value to EBITDA -6.17 | Shares Outstanding 30631794 | Shares Floating 30285655 |
Shares Outstanding 30631794 | Shares Floating 30285655 | ||
Percent Insiders 0.79 | Percent Institutions 15.86 |
Upturn AI SWOT
Avita Medical Ltd
Company Overview
History and Background
Avita Medical Ltd. was founded in 1993 as a biotechnology company focused on regenerative medicine. A significant milestone was the development and FDA approval of the RECELL System for the treatment of severe burns. The company has evolved to focus on commercializing its patented spray-on skin cell technology for a range of dermatological conditions.
Core Business Areas
- Regenerative Medicine Technology: Avita Medical's core business revolves around its proprietary Spray-On Skinu2122 technology, which enables the delivery of a patient's own skin cells to wounds and skin defects. This technology aims to accelerate healing and improve outcomes for a variety of dermatological conditions.
Leadership and Structure
Avita Medical Ltd. is led by a management team with expertise in biotechnology, commercialization, and regulatory affairs. The company operates as a publicly traded entity with a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- RECELL System: The RECELL System is Avita Medical's flagship product, an autologous (from the patient's own body) skin-grafting device that uses a suspension of the patient's skin cells to treat severe full-thickness burns. It received FDA approval in 2018. Competitors include traditional skin grafting methods and other advanced wound care solutions, though direct competitors for this specific spray-on autologous cell therapy are limited. Market share data for this niche is not readily available but is growing as adoption increases.
Market Dynamics
Industry Overview
Avita Medical operates in the regenerative medicine and advanced wound care market. This sector is characterized by rapid technological innovation, significant research and development investment, and a growing demand for less invasive and more effective treatment options for chronic wounds, burns, and other skin conditions.
Positioning
Avita Medical is positioned as a pioneer in spray-on autologous skin cell therapy. Its key competitive advantage lies in its patented RECELL technology, which offers a unique approach to wound healing by utilizing a patient's own cells. The company is focused on expanding the indications for its technology and increasing market penetration.
Total Addressable Market (TAM)
The global wound care market is substantial and growing, with estimates for the advanced wound care segment alone reaching tens of billions of dollars annually. Avita Medical is positioned to capture a significant portion of this market for specific indications like severe burns, vitiligo, and potentially other skin reconstructive needs, though it currently addresses a smaller, specialized segment within the broader TAM.
Upturn SWOT Analysis
Strengths
- Proprietary Spray-On Skinu2122 technology (RECELL System)
- FDA approval for severe burn treatment
- Autologous cell therapy offers potential for reduced rejection and improved healing
- Experienced management team
Weaknesses
- Limited product portfolio with reliance on RECELL System
- High cost of treatment and potential reimbursement challenges
- Need for specialized training for healthcare professionals
- Scalability of manufacturing and distribution
Opportunities
- Expansion of indications for RECELL System (e.g., vitiligo, reconstructive surgery)
- Partnerships and collaborations for market expansion
- Growing global demand for advanced wound care solutions
- Advancements in cell therapy and regenerative medicine
Threats
- Competition from established wound care companies and emerging technologies
- Regulatory hurdles for new indications and market approvals
- Reimbursement policies and pricing pressures
- Potential for adverse events or clinical trial failures
Competitors and Market Share
Key Competitors
- Smith & Nephew (SNN)
- Organogenesis Holdings Inc. (ORGO)
- Misonix, Inc. (MSON)
Competitive Landscape
Avita Medical's advantage lies in its unique autologous spray-on skin technology for severe burns. Competitors like Smith & Nephew and Organogenesis offer a broader range of advanced wound care products, including biological grafts and other regenerative therapies, often with more established market presence and reimbursement pathways. Avita's challenge is to differentiate its technology and prove its superiority and cost-effectiveness across broader indications.
Growth Trajectory and Initiatives
Historical Growth: Avita Medical has demonstrated growth in its revenue from the commercialization of the RECELL System. This growth is driven by increasing adoption by burn centers and expansion into new geographic markets.
Future Projections: Future projections are dependent on the successful expansion of indications for the RECELL System, market penetration in existing and new regions, and potential new product development. Analyst estimates would provide a basis for these projections.
Recent Initiatives: Recent initiatives likely include expanding the sales force, securing reimbursement for the RECELL System, pursuing regulatory approvals for new indications (such as vitiligo), and ongoing clinical studies to support broader use of their technology.
Summary
Avita Medical Ltd. is a promising regenerative medicine company with a groundbreaking spray-on skin technology, RECELL System, approved for severe burns. Its key strengths lie in its proprietary technology and FDA approval. However, it faces challenges in market penetration, cost of treatment, and competition from broader wound care portfolios. Successful expansion into new indications and securing favorable reimbursement will be critical for its future growth and profitability. The company needs to carefully manage its investments while demonstrating clinical and economic value to stakeholders.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company investor relations reports
- Financial news outlets
- Industry analysis reports
- FDA databases
Disclaimers:
This information is for informational purposes only and does not constitute investment advice. Financial data and market share estimates are subject to change and may vary based on the source and reporting period. Investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avita Medical Ltd
Exchange NASDAQ | Headquaters Valencia, CA, United States | ||
IPO Launch date 2019-10-01 | Executive Chairman & Interim CEO Mr. Cary G. Vance | ||
Sector Healthcare | Industry Medical Devices | Full time employees 226 | Website https://avitamedical.com |
Full time employees 226 | Website https://avitamedical.com | ||
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.